# A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct01989754` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01989754](<https://clinicaltrials.gov/study/NCT01989754>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01989754

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5813 participants.

## Technical summary

Registry record NCT01989754. Randomized; quadruple masking; primary purpose treatment. Start 2014-01-16 (actual); primary completion 2017-02-23 (actual). Results posted on 2018-12-11.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 5813 participants (enrolled count; ClinicalTrials.gov record NCT01989754, source copy `cardio:ctgov-nct01989754-2018-12-11`, retrieved 2026-10-26)
- Started: 2014-01-16 (actual) (ClinicalTrials.gov record NCT01989754, source copy `cardio:ctgov-nct01989754-2018-12-11`, retrieved 2026-10-26)
- Primary completion: 2017-02-23 (actual) (ClinicalTrials.gov record NCT01989754, source copy `cardio:ctgov-nct01989754-2018-12-11`, retrieved 2026-10-26)
- Completion: 2017-02-23 (actual) (ClinicalTrials.gov record NCT01989754, source copy `cardio:ctgov-nct01989754-2018-12-11`, retrieved 2026-10-26)
- Results first posted: 2018-12-11 (ClinicalTrials.gov record NCT01989754, source copy `cardio:ctgov-nct01989754-2018-12-11`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Belgium; Brazil; Canada; China; Czechia; France; Germany; Hungary; Italy; Malaysia; Mexico; Netherlands; New Zealand; Poland; Puerto Rico; Russia; South Korea; Spain; Sweden; Taiwan; Ukraine; United Kingdom (ClinicalTrials.gov record NCT01989754, source copy `cardio:ctgov-nct01989754-2018-12-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01989754-2018-12-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus
- Acronym: CANVAS-R
- Condition: Diabetes Mellitus, Type 2
- Condition: Albuminuria
- Intervention (Drug): Placebo
- Intervention (Drug): Canagliflozin, 100 mg
- Intervention (Drug): Canagliflozin, 300 mg
- Lead sponsor: Janssen Research & Development, LLC
- Lead sponsor class: INDUSTRY
- Collaborator: The George Institute for Global Health, Australia
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Janssen Research & Development, LLC (`cardio:org-janssen-research-development-llc`)
- Registry lists this organization as a collaborator: The George Institute for Global Health (`core:george-institute`)

## Provenance

Content hash: 06b66e9e795bc702c4ca10f61ef64baee2a21fd2c603ac394b378248b6207e0a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
